Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-22T18:24:43.513Z Has data issue: false hasContentIssue false
  • English
  • Français

Beyond the pill: new medication delivery options for ADHD

Published online by Cambridge University Press:  07 July 2017

Andrew J. Cutler  and
Gregory W. Mattingly
Andrew J. Cutler*
Affiliation:
Chief Medical Officer, Florida Clinical Research Center, Bradenton, Florida
Gregory W. Mattingly
Affiliation:
Department of Psychiatry, Washington University in St. Louis, St. Louis, Missouri Midwest Research Group, Weldon Spring, Missouri
*
*Address for correspondence: Andrew J. Cutler, Florida Clinical Research Center, 8043 Cooper Creek Boulevard, Suite 107, Bradenton, Florida 34201. (Email: [email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Successful treatment of pediatric disorders has necessitated the development of alternative medication formulations, as children may prefer alternative dosage forms to tablets or capsules. This is especially true for attention-deficit/hyperactivity disorder (ADHD), which is one of the most common chronic pediatric conditions and often involves children with a variety of overlapping physical, psychological, or neurodevelopmental disorders. A special challenge for developing alternative dosage forms for ADHD treatment is the incorporation of a once-daily long-acting formulation. Traditional ADHD medication formulations have been limited, and issues surrounding prescribed dosing regimens—including poor medication adherence, difficulty swallowing, and the lack of dosing titration options—persist in ADHD treatment. In other disease areas, the development of alternative formulations has provided options for patients who have issues with consuming solid dosage forms, particularly children and individuals with developmental disorders. In the light of these new developments, several alternative formulations for ADHD medications are under development or have recently become available. This article reviews the various strategies for developing alternative dosage forms in other disease areas and discusses the application of these strategies in ADHD treatment. Alternative dosage forms may increase medication adherence, compliance, and patient preference and, therefore, improve the overall treatment for ADHD.

Keywords

Attention-deficit/hyperactivity disorderformulationstimulant
Type
Review Articles
Information
CNS Spectrums , Volume 22 , Issue 6 , December 2017 , pp. 463 - 474
Copyright
© Cambridge University Press 2016 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Writing and editorial support were provided by Liqing Xiao and Jennifer Tyson of AlphaBioCom LLC, and funded by Neos Therapeutics Inc.

References

1. Ivanovska, V, Rademaker, CM, van Dijk, L, Mantel-Teeuwisse, AK. Pediatric drug formulations: a review of challenges and progress. Pediatrics. 2014; 134(2): 361–372. Epub ahead of print Jul 14. http://pediatrics.aappublications.org/content/134/2/361.long. Accessed December 30, 2016.Google Scholar
2. Patel, A, Jacobsen, L, Jhaveri, R, Bradford, KK. Effectiveness of pediatric pill swallowing interventions: a systematic review. Pediatrics. 2015; 135(5): 883–889. http://pediatrics.aappublications.org/content/135/5/883.long. Accessed December 30, 2016.CrossRefGoogle ScholarPubMed
3. Strickley, RG, Iwata, Q, Wu, S, Dahl, TC. Pediatric drugs—a review of commercially available oral formulations. J Pharm Sci. 2008; 97(5): 1731–1774.Google Scholar
4. Pliszka, S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007; 46(7): 894–921. http://www.jaacap.com/article/S0890-8567(09)62182-1/pdf. Accessed December 30, 2016.Google Scholar
5. American Academy of Pediatrics. ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents; 2011. http://pediatrics.aappublications.org/content/early/2011/10/14/peds.2011-2654. Accessed December 30, 2016.Google Scholar
6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Washington, DC: American Psychiatric Association; 2013.Google Scholar
7. Centers for Disease Control and Prevention. Asthma and Schools; 2015. http://www.cdc.gov/healthyschools/asthma/index.htm. Accessed September 14, 2016.Google Scholar
8. Kessler, RC, Adler, L, Barkley, R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006; 163(4): 716–723. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2859678/pdf/nihms176779.pdf. Accessed December 30, 2016.Google Scholar
9. Kessler, RC, Berglund, P, Demler, O, Jin, R, Merikangas, KR, Walters, EE. Lifetime prevalence and age-of-onset distributions of DSM–IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005; 62(6): 593–602. http://jamanetwork.com/journals/jamapsychiatry/fullarticle/208678. Accessed December 30, 2016. Erratum in Arch Gen Psychiatry. 2005; 62(7): 768.Google Scholar
10. National Institute for Health and Care Excellence. Attention Deficit Hyperactivity Disorder: Diagnosis and Management Clinical Guideline. https://www.nice.org.uk/guidance/cg72. Accessed December 30, 2016.Google Scholar
11. Post, RE, Kurlansik, SL. Diagnosis and management of adult attention-deficit/hyperactivity disorder. Am Fam Physician. 2012; 85(9): 890–896. http://www.aafp.org/afp/2012/0501/p890.html. Accessed December 30, 2016.Google ScholarPubMed
12. Wolraich, M, Brown, L, Brown, RT, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011; 128(5): 1007–1022. Epub ahead of print Oct 16. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500647/pdf/nihms701937.pdf. Accessed December 30, 2016.Google ScholarPubMed
13. Rabito-Alcon, MF, Correas-Lauffer, J. Treatment guidelines for attention deficit and hyperactivity disorder: a critical review. Actas Esp Psiquiatr. 2014; 42(6): 315–324. Epub ahead of print Nov 1. https://www.actaspsiquiatria.es/repositorio//16/92/ENG/16-92-ENG-315-324-893879.pdf. Accessed December 30, 2016.Google Scholar
14. Barbaresi, WJ, Katusic, SK, Colligan, RC, Weaver, AL, Jacobsen, SJ. Modifiers of long-term school outcomes for children with attention-deficit/hyperactivity disorder: does treatment with stimulant medication make a difference? Results from a population-based study. J Dev Behav Pediatr. 2007; 28(4): 274–287.CrossRefGoogle ScholarPubMed
15. Mészáros, A, Czobor, P, Bálint, S, Komlósi, S, Simon, V, Bitter, I. Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis. Int J Neuropsychopharmacol. 2009; 12(8): 1137–1147. Epub ahead of print Jul 7. http://ijnp.oxfordjournals.org/content/12/8/1137.long. Accessed December 30, 2016.Google Scholar
16. Ramos-Quiroga, JA, Bosch, R, Castells, X, et al. Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate: a chart review of Spanish adults with attention-deficit hyperactivity disorder. CNS Drugs. 2008; 22(7): 603–611.Google Scholar
17. Ahmed, R, Aslani, P. Attention-deficit/hyperactivity disorder: an update on medication adherence and persistence in children, adolescents and adults. Expert Rev Pharmacoecon Outcomes Res. 2013; 13(6): 791–815.Google Scholar
18. Beck, MH, Cataldo, M, Slifer, KJ, Pulbrook, V, Guhman, JK. Teaching children with attention deficit hyperactivity disorder (ADHD) and autistic disorder (AD) how to swallow pills. Clin Pediatr (Phila). 2005; 44(6): 515–526.Google Scholar
19. McCarthy, S. Pharmacological interventions for ADHD: how do adolescent and adult patient beliefs and attitudes impact treatment adherence? Patient Prefer Adherence. 2014; 8: 1317–1327. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4181644/pdf/ppa-8-1317.pdf. Accessed December 30, 2016.Google Scholar
20. Childress, AC, Sallee, FR, Berry, SA. Single-dose pharmacokinetics of NWP06, an extended-release methylphenidate suspension, in children and adolescents with ADHD. Postgrad Med. 2011; 123(5): 80–88.Google Scholar
21. Nadon, G, Feldman, D, Gisel, E. Feeding issues associated with the autism spectrum disorders. In Fitzgerald M, ed. Recent Advances in Autism Spectrum Disorders. Winchester: InTech; 2013:Vol. 1, Chap. 25. http://www.intechopen.com/books/recent-advances-in-autism-spectrum-disorders-volume-i/feeding-issues-associated-with-the-autism-spectrum-disorders. Accessed December 30, 2016.Google Scholar
22. Barnhill, K, Tami, A, Schutte, C, Hewitson, L, Olive, ML. Targeted nutritional and behavioral feeding intervention for a child with autism spectrum disorder. Case Rep Psychiatry. 2016; 2016: 1420549. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4804042/pdf/CRIPS2016-1420549.pdf. Accessed December 30, 2016.Google ScholarPubMed
23. Parker, C. Pharmacological treatments for ADHD. Prog Neurol Psychiatry. 2013; 17(4): 11–20. http://onlinelibrary.wiley.com/doi/10.1002/pnp.289/pdf. Accessed December 30, 2016.Google Scholar
24. Methylin® Oral Solution, Methylphenidate HCl Oral Solution, CII Full Prescribing Information. Shionogi Inc., Florham Park, NJ; 2013. http://www.empr.com/methylin-oral-solution/drug/521/. Accessed December 30, 2016.Google Scholar
25. Quillichew ER™ (Methylphenidate Hydrochloride) Extended-Release Chewable Tablets, for Oral Use, CII Full Prescribing Information. NextWave Pharmaceuticals, a Subsidiary of Pfizer, New York; 2015. https://www.pfizermedicalinformation.com/en-us/quillichew-er. Accessed December 30, 2016.Google Scholar
26. Quillivant® XR (Methylphenidate Hydrochloride) for Extended-Release Oral Suspension, CII Full Prescribing Information. NextWave Pharmaceuticals, a Subsidiary of Pfizer, New York; 2015.Google Scholar
27. Vyvanse® (Lisdexamfetamine Dimesylate) Capsules, for Oral Use, CII Full Prescribing Information. Shire US Inc., Wayne, PA; 2015.Google Scholar
28. DyanavelTM XR (Amphetamine) Extended-Release Oral Suspension, CII Full Prescribing Information. Tris Pharma, Monmouth Junction, NJ; 2015.Google Scholar
29. Adzenys XR–ODT™ (Amphetamine Extended-Release Orally Disintegrating Tablets), CII Full Prescription Information. Neos Therapeutics LP, Grand Prairie, TX; 2015.Google Scholar
30. Warshaw, EM, Squires, L, Li, Y, Civil, R, Paller, AS. Methylphenidate transdermal system: a multisite, open-label study of dermal reactions in pediatric patients diagnosed with ADHD. Prim Care Companion J Clin Psychiatry. 2010; 12(6): pii: PCC.10m00996. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3067997/. Accessed December 30, 2016.Google ScholarPubMed
31. Perwien, A, Hall, J, Swensen, A, Swindle, R. Stimulant treatment patterns and compliance in children and adults with newly treated attention-deficit/hyperactivity disorder. J Manag Care Pharm. 2004; 10(2): 122–129. http://www.jmcp.org/doi/pdf/10.18553/jmcp.2004.10.2.122. Accessed December 30, 2016.Google Scholar
32. Winterstein, AG, Gerhard, T, Shuster, J, et al. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database. Ann Pharmacother. 2008; 42(1): 24–31. http://journals.sagepub.com/doi/pdf/10.1345/aph.1K143. Accessed December 30, 2016.Google Scholar
33. Gee, SC, Hagemann, TM. Palatability of liquid anti-infectives: clinician and student perceptions and practice outcomes. J Pediatr Pharmacol Ther. 2007; 12(4): 216–223. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3462086/pdf/i1551-6776-12-4-216.pdf. Accessed December 30, 2016.Google Scholar
34. Fini, A, Bergamante, V, Ceschel, GC, Ronchi, C, de Moraes, CA. Fast dispersible/slow releasing ibuprofen tablets. Eur J Pharm Biopharm. 2008; 69(1): 335–341.Google Scholar
35. Scott, CS, Retsch-Bogart, GZ, Kustra, RP, Graham, KM, Glasscock, BJ, Smith, PC. The pharmacokinetics of ibuprofen suspension, chewable tablets, and tablets in children with cystic fibrosis. J Pediatr. 1999; 134(1): 58–63. http://www.jpeds.com/article/S0022-3476(99)70387-2/pdf. Accessed December 30, 2016.Google Scholar
36. Cox, L. Sublingual immunotherapy in pediatric allergic rhinitis and asthma: efficacy, safety, and practical considerations. Curr Allergy Asthma Rep. 2007; 7(6): 410–420.Google Scholar
37. Occasi, F, De Castro, G, Zicari, AM, Indinnimeo, L, Tancredi, G, Duse, M. Sublingual immunotherapy in children and its potential beneficial collateral effect on respiratory tract infections. Curr Med Res Opin. 2015; 31(5): 939–941. Epub ahead of print Mar 31.Google Scholar
38. Vadlamudi, A, Shaker, M. New developments in allergen immunotherapy. Curr Opin Pediatr. 2015; 27(5): 649–655.Google Scholar
39. Wertheimer, AI, Santella, TM, Finestone, AJ, Levy, RA. Drug delivery systems improve pharmaceutical profile and facilitate medication adherence. Adv Ther. 2005; 22(6): 559–577.Google Scholar
40. Kathpalia, H, Sule, B, Patil, A, Mahadik, A, Sharma, K. Controlled release orally disintegrating tablets: a review. Int J Pharm Sci Rev Res. 2014; 24(1): 35–42. http://globalresearchonline.net/journalcontents/v24-1/07.pdf. Accessed December 30, 2016.Google Scholar
41. Wei, Q, Yang, F, Luan, L. Preparation and in vitro/in vivo evaluation of a ketoprofen orally disintegrating/sustained release tablet. Drug Dev Ind Pharm. 2013; 39(6): 928–934. Epub ahead of print Mar 8, 2012.CrossRefGoogle ScholarPubMed
42. Liu, P, Fang, AF, LaBadie, RR, Crownover, PH, Arguedas, AG. Comparison of azithromycin pharmacokinetics following single oral doses of extended-release and immediate-release formulations in children with acute otitis media. Antimicrob Agents Chemother. 2011; 55(11): 5022–5026. Epub ahead of print Aug 22. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3195035/pdf/zac5022.pdf. Accessed December 30, 2016.CrossRefGoogle ScholarPubMed
43. Pergolizzi, JV Jr, Scholten, W, Smith, KJ, Leighton-Scott, J, Willis, JC, Henningfield, JE. The unique role of transdermal buprenorphine in the global chronic pain epidemic. Acta Anaesthesiol Taiwan. 2015; 53(2): 71–76. Epub ahead of print Jul 21. http://www.e-aat.com/article/S1875-4597(15)00052-1/pdf. Accessed December 30, 2016.Google Scholar
44. Keith, S. Advances in psychotropic formulations. Prog Neuropsychopharmacol Biol Psychiatry. 2006; 30(6): 996–1008. Epub ahead of print May 6.Google Scholar
45. Nordstrom, K, Allen, MH. Alternative delivery systems for agents to treat acute agitation: progress to date. Drugs. 2013; 73(16): 1783–1792.CrossRefGoogle ScholarPubMed
46. Dey, P, Maiti, S. Orodispersible tablets: a new trend in drug delivery. J Nat Sci Biol Med. 2010; 1(1): 2–5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3217286/. Accessed December 30, 2016.Google Scholar
47. San, L, Casillas, M, Ciudad, A, Gilaberte, I. Olanzapine orally disintegrating tablet: a review of efficacy and compliance. CNS Neurosci Ther. 2008; 14(3): 203–214.Google Scholar
48. Johnson, SB. Medical Regimen Adherence in the Management of Diabetes: What Psychologists Need to Know. Washington, DC: American Psychological Association; 2012. www.apa.org/about/governance/president/medical-regimen-diabetes.pdf. Accessed December 30, 2016.Google Scholar
49. Tajeu, GS, Kent, ST, Kronish, IM, et al. Trends in antihypertensive medication discontinuation and low adherence among Medicare beneficiaries initiating treatment from 2007 to 2012. Hypertension. 2016; 68(3): 565–575. Epub ahead of print Jul 18.Google Scholar
50. Kane, JM, Kishimoto, T, Correll, CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry. 2013; 12(3): 216–226. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3799245/pdf/wps0012-0216.pdf. Accessed December 30, 2016.CrossRefGoogle ScholarPubMed
51. Patel, MX, David, SA. Medication adherence: predictive factors and enhancement strategies. Psychiatry. 2007; 6(9): 357–361.Google Scholar
52. Burton, SC. Strategies for improving adherence to second-generation antipsychotics in patients with schizophrenia by increasing ease of use. J Psychiatr Pract. 2005; 11(6): 369–378.Google Scholar
53. Velligan, DI, Weiden, PJ, Sajatovic, M, et al. Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines. J Psychiatr Pract. 2010; 16(5): 306–324.Google Scholar
54. Nemeroff, CB. Improving antidepressant adherence. J Clin Psychiatry. 2003; 64(Suppl 18): 25–30.Google Scholar
55. Antonini, A, Calandrella, D. Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson’s disease: implications for patients. Neuropsychiatr Dis Treat. 2011; 7: 297–302. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3101890/pdf/ndt-7-297.pdf. Accessed December 30, 2016.Google Scholar
56. Herrmann, N, Binder, C, Dalziel, W, Smyth, S, Camacho, F. Persistence with cholinesterase inhibitor therapy for dementia: an observational administrative health database study. Drugs Aging. 2009; 26(5): 403–407.Google Scholar
57. Bitter, I, Treuer, T, Dilbaz, N, et al. Patients’ preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study. World J Biol Psychiatry. 2010; 11(7): 894–903. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2981076/pdf/swbp11-894.pdf. Accessed December 30, 2016.Google Scholar
58. Czekalla, J, Wagner, T, Schacht, A, Kluge, M, Kinon, B. Effectiveness and medication acceptance of olanzapine disintegrating tablets compared to standard olanzapine tablets in acutely treated psychiatric patients. Patient Prefer Adherence. 2007; 1: 19–27. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2779125/pdf/ppa-1-019.pdf. Accessed December 30, 2016.Google Scholar
59. Karagianis, J, Grossman, L, Landry, J, et al. A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: the PLATYPUS Study. Schizophr Res. 2009; 113(1): 41–48. Epub ahead of print Jun 16.Google Scholar
60. Kinon, BJ, Hill, AL, Liu, H, Kollack-Walker, S. Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia. Int J Neuropsychopharmacol. 2003; 6(2): 97–102. http://ijnp.oxfordjournals.org/content/ijnp/6/2/97.full.pdf. Accessed December 30, 2016.Google Scholar
61. Kusumi, I, Honda, M, Ito, K, et al. Risperidone oral solution versus standard tablets for the acute treatment of patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011; 35(2): 537–540. Epub ahead of print Dec 17, 2010.Google Scholar
62. Danileviciute, V, Sveikata, A, Adomaitiene, V, Gumbrevicius, G, Fokas, V, Sveikatiene, R. Efficacy, tolerability, and preference of mirtazapine orally disintegrating tablets in depressed patients: a 17-week naturalistic study in Lithuania. Medicina (Kaunas). 2009; 45(10): 778–784. http://medicina.lsmuni.lt/med/0910/0910-04e.htm. Accessed December 30, 2016.Google Scholar
63. Saphris® Sublingual Tablets, Full Prescribing Information. Forest Pharmaceuticals Inc., a Subsidiary of Forest Laboratories, St. Louis, Missouri; 2015.Google Scholar
64. Erdman, K, Stypinski, D, Combs, M, Witt, P, Stiles, M, Pollock, S. Absence of food effect on the extent of alprazolam absorption from an orally disintegrating tablet. Pharmacotherapy. 2007; 27(8): 1120–1124.Google Scholar
65. Shirsand, SB, Suresh, S, Jodhana, LS, Swamy, PV. Formulation design and optimization of fast disintegrating lorazepam tablets by effervescent method. Indian J Pharm Sci. 2010; 72(4): 431–436. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3013557/. Accessed December 30, 2016.Google Scholar
66. Susman, J, Klee, B. The role of high-potency benzodiazepines in the treatment of panic disorder. Prim Care Companion J Clin Psychiatry. 2005; 7(1): 5–11. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1076453/pdf/i1523-5998-7-1-5.pdf. Accessed December 30, 2016.Google Scholar
67. Gajria, K, Lu, M, Sikirica, V, et al. Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder: a systematic literature review. Neuropsychiatr Dis Treat. 2014; 10: 1543–1569. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4149449/pdf/ndt-10-1543.pdf. Accessed December 30, 2016.Google Scholar
68. Lopez, FA, Leroux, JR. Long-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate to address continuing clinical challenges. Atten Defic Hyperact Disord. 2013; 5(3): 249–265. Epub ahead of print Apr 6. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751218/pdf/12402_2013_Article_106.pdf. Accessed December 30, 2016.CrossRefGoogle ScholarPubMed
69. Greenhill, LL, Abikoff, HB, Arnold, LE, et al. Medication treatment strategies in the MTA Study: relevance to clinicians and researchers. J Am Acad Child Adolesc Psychiatry. 1996; 35(10): 1304–1313.Google Scholar
70. Antshel, KM, Hargrave, TM, Simonescu, M, Kaul, P, Hendricks, K, Faraone, SV. Advances in understanding and treating ADHD. BMC Med. 2011; 9: 72 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3126733/pdf/1741-7015-9-72.pdf. Accessed December 30 2016.Google Scholar
71. Buitelaar, J, Medori, R. Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefits of long-acting stimulants. Eur Child Adolesc Psychiatry. 2010; 19(4): 325–340. Epub ahead of print Oct 13, 2009. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2843838/pdf/787_2009_Article_56.pdf. Accessed December 30, 2016.Google Scholar
72. Olfson, M. New options in the pharmacological management of attention-deficit/hyperactivity disorder. Am J Manag Care. 2004; 10(4 Suppl): S117–S124. http://www.ajmc.com/journals/supplement/2004/2004-07-vol10-n4Suppl/Jul04-1819pS117-S124/. Accessed December 30, 2016.Google Scholar
73. Swanson, JM, Wigal, S, Greenhill, LL, et al. Analog classroom assessment of Adderall in children with ADHD. J Am Acad Child Adolesc Psychiatry. 1998; 37(5): 519–526.Google Scholar
74. Swanson, J. Compliance with stimulants for attention-deficit/hyperactivity disorder: issues and approaches for improvement. CNS Drugs. 2003; 17(2): 117–131.Google Scholar
75. Wolraich, ML, Greenhill, LL, Pelham, W, et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics. 2001; 108(4): 883–892.Google Scholar
76. Maldonado, R. Comparison of the pharmacokinetics and clinical efficacy of new extended-release formulations of methylphenidate. Expert Opin Drug Metab Toxicol. 2013; 9(8): 1001–1014. Epub ahead of print Apr 23.Google Scholar
77. Punja, S, Zorzela, L, Hartling, L, Urichuk, L, Vohra, S. Long-acting versus short-acting methylphenidate for paediatric ADHD: a systematic review and meta-analysis of comparative efficacy. BMJ Open. 2013; 3(3): pii: e002312. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612754/pdf/bmjopen-2012-002312.pdf. Accessed December 30, 2016.Google Scholar
78. Maneeton, B, Maneeton, N, Likhitsathian, S, et al. Comparative efficacy, acceptability, and tolerability of lisdexamfetamine in child and adolescent ADHD: a meta-analysis of randomized, controlled trials. Drug Des Devel Ther. 2015; 9: 1927–1936. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389815/pdf/dddt-9-1927.pdf. Accessed December 30, 2016.Google Scholar
79. Adler, LA, Zimmerman, B, Starr, HL, et al. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. J Clin Psychopharmacol. 2009; 29(3): 239–247.Google Scholar
80. Dopfner, M, Gerber, WD, Banaschewski, T, et al. Comparative efficacy of once-a-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting. Eur Child Adolesc Psychiatry. 2004; 13(Suppl 1): I93–101.Google Scholar
81. Findling, RL, Quinn, D, Hatch, SJ, Cameron, SJ, DeCory, HH, McDowell, M. Comparison of the clinical efficacy of twice-daily Ritalin and once-daily Equasym XL with placebo in children with attention deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry. 2006; 15(8): 450–459. Epub ahead of print Jun 21.Google Scholar
82. Kemner, JE, Lage, MJ. Effect of methylphenidate formulation on treatment patterns and use of emergency room services. Am J Health Syst Pharm. 2006; 63(4): 317–322.Google Scholar
83. Feldman, M, Bélanger, S. Extended-release medications for children and adolescents with attention-deficit hyperactivity disorder. Paediatr Child Health. 2009; 14(9): 593–602. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2806078/pdf/pch14593.pdf. Accessed December 30, 2016.Google Scholar
84. Lachaine, J, Beauchemin, C, Sasane, R, Hodgkins, PS. Treatment patterns, adherence, and persistence in ADHD: a Canadian perspective. Postgrad Med. 2012; 124(3): 139–148.Google Scholar
85. Christensen, L, Sasané, R, Hodgkins, P, Harley, C, Tetali, S. Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population. Curr Med Res Opin. 2010; 26(4): 977–989.Google Scholar
86. Modesto-Lowe, V, Chaplin, M, Sinha, S, Woodard, K. Universal precautions to reduce stimulant misuse in treating adult ADHD. Cleve Clin J Med. 2015; 82(8): 506–512. http://www.mdedge.com/ccjm/article/101415/adolescent-medicine/universal-precautions-reduce-stimulant-misuse-treating-adult. Accessed December 30, 2016.Google Scholar
87. Wilens, TE, Adler, LA, Adams, J, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry. 2008; 47(1): 21–31.Google Scholar
88. Barner, JC, Khoza, S, Oladapo, A. ADHD medication use, adherence, persistence and cost among Texas Medicaid children. Curr Med Res Opin. 2011; 27(Suppl 2): 13–22.Google Scholar
89. Brinkman, WB, Sherman, SN, Zmitrovich, AR, et al. Parental angst making and revisiting decisions about treatment of attention-deficit/hyperactivity disorder. Pediatrics. 2009; 124(2): 580–589. Epub ahead of print Jul 27. http://pediatrics.aappublications.org/content/124/2/580.long. Accessed December 30, 2016.Google Scholar
90. Gau, SS, Chen, SJ, Chou, WJ, et al. National survey of adherence, efficacy, and side effects of methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. J Clin Psychiatry. 2008; 69(1): 131–140.Google Scholar
91. Peters, K, Jackson, D. Mothers’ experiences of parenting a child with attention deficit hyperactivity disorder. J Adv Nurs. 2009; 65(1): 62–71.Google Scholar
92. Bussing, R, Koro-Ljungberg, M, Noguchi, K, Mason, D, Mayerson, G, Garvan, CW. Willingness to use ADHD treatments: a mixed methods study of perceptions by adolescents, parents, health professionals and teachers. Soc Sci Med. 2012; 74(1): 92–100. Epub ahead of print Nov 17, 2011. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3253014/pdf/nihms342173.pdf. Accessed December 30, 2016.Google Scholar
93. Charach, A, Fernandez, R. Enhancing ADHD medication adherence: challenges and opportunities. Curr Psychiatry Rep. 2013; 15(7): 371. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3718998/pdf/11920_2013_Article_371.pdf. Accessed December 30, 2016.Google Scholar
94. Taddeo, D, Egedy, M, Frappier, JY. Adherence to treatment in adolescents. Paediatr Child Health. 2008; 13(1): 19–24. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2528818/pdf/pch13019.pdf. Accessed December 30, 2016.Google Scholar
95. Adler, LA, Lynch, LR, Shaw, DM, et al. Medication adherence and symptom reduction in adults treated with mixed amphetamine salts in a randomized crossover study. Postgrad Med. 2011; 123(5): 71–79.Google Scholar
96. Palli, SR, Kamble, PS, Chen, H, Aparasu, RR. Persistence of stimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2012; 22(2): 139–148. Epub ahead of print Feb 24.Google Scholar
97. Tzang, RF, Wang, YC, Yeh, CB, et al. Naturalistic exploration of the effect of osmotic release oral system-methylphenidate on remission rate and functional improvement in Taiwanese children with attention-deficit-hyperactivity disorder. Psychiatry Clin Neurosci. 2012; 66(1): 53–63.Google Scholar
98. Chou, WJ, Chou, MC, Tzang, RF, et al. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes. Psychiatry Clin Neurosci. 2009; 63(2): 167–175. http://onlinelibrary.wiley.com/doi/10.1111/j.1440-1819.2009.01937.x/pdf. Accessed December 30, 2016.Google Scholar
99. Marquis, J, Schneider, MP, Payot, V, et al. Swallowing difficulties with oral drugs among polypharmacy patients attending community pharmacies. Int J Clin Pharm. 2013; 35(6): 1130–1136. Epub ahead of print Aug 21.Google Scholar
100. Schiele, JT, Quinzler, R, Klimm, HD, Pruszydlo, MG, Haefeli, WE. Difficulties swallowing solid oral dosage forms in a general practice population: prevalence, causes, and relationship to dosage forms. Eur J Clin Pharmacol. 2013; 69(4): 937–948.Google Scholar
101. Palmer, JB, Drennan, JC, Baba, M. Evaluation and treatment of swallowing impairments. Am Fam Physician. 2000; 61(8): 2453–2462. http://www.aafp.org/afp/2000/0415/p2453.html. Accessed December 30, 2016.Google Scholar
102. Polaha, J, Dalton, WT 3rd, Lancaster, BM. Parental report of medication acceptance among youth: implications for everyday practice. South Med J. 2008; 101(11): 1106–1112.Google Scholar
103. Metadate CD® (Methylphenidate HCl, USP) Extended-Release Capsules, CII Full Prescribing Information. UCB Inc., Smyrna, GA; 2014.Google Scholar
104. Ritalin LA® (Methylphenidate Hydrochloride) Extended-Release Capsules, CII Full Prescribing Information. Novartis Pharmaceuticals Corporation, East Hanover, NJ; 2015.Google Scholar
105. Adderall XR® (Mixed Salts of a Single-Entity Amphetamine Product) Dextroamphetamine Sulfate, Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Amphetamine Sulfate Capsules, CII Full Prescribing Information. Shire US Inc., Wayne, PA; 2015.Google Scholar
106. Focalin, XR. (Dexmethylphenidate Hydrochloride) Extended-Release Capsules, CII for Oral Use Full Prescribing Information. Novartis Pharmaceuticals Corporation, East Hanover, NJ; 2015.Google Scholar
107. Aptensio XR™ (Methylphenidate Hydrochloride) Extended-Release Capsules for Oral Use, CII Full Prescribing Information. Rhodes Pharmaceuticals LP, Coventry, RI; 2015.Google Scholar
108. Squires, LA, Lombardi, DP, Sjostedt, P, Thompson, CA. A systematic literature review on the assessment of palatability and swallowability in the development of oral dosage forms for pediatric patients. Ther Innov Regul Sci. 2013; 47(5): 533–541.Google Scholar
109. Daytrana® (Methylphenidate Transdermal System) Full Prescribing Information. Noven Pharmaceuticals Inc., Miami, FL; 2015.Google Scholar
110. Patrick, KS, Straughn, AB, Perkins, JS, Gonzalez, MA. Evolution of stimulants to treat ADHD: transdermal methylphenidate. Hum Psychopharmacol. 2009; 24(1): 1–17. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2629554/pdf/nihms-86228.pdf. Accessed December 30, 2016.Google Scholar
111. Methylin® Chewable Tablets (Methylphenidate HCl) Chewable Tablets, CII Full Prescribing Information. Shionogi Inc., Florham Park, NJ; 2013.Google Scholar
112. Childress, A, Newcorn, J, Stark, JG, McMahen, R, Tengler, M, Sikes, C. A Single-dose, single-period pharmacokinetic assessment of an extended-release orally disintegrating tablet of methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2016; 26(6): 505–512. Epub ahead of print May 26. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4991613/pdf/cap.2015.0261.pdf. Accessed December 30, 2016.Google Scholar
113. Childress, AC, Kollins, SH, Cutler, AJ, Marraffino, A, Sikes, CR. Efficacy, Safety, and tolerability of an extended-release orally disintegrating methylphenidate tablet in children 6–12 years of age with attention-deficit/hyperactivity disorder in the laboratory classroom setting. J Child Adolesc Psychopharmacol. 2017 Feb; 27(1): 66–74. Epub ahead of print May 16. http://online.liebertpub.com/doi/pdfplus/10.1089/cap.2016.0002. Accessed December 31, 2016.Google Scholar
114. Adler, LD, Nierenberg, AA. Review of medication adherence in children and adults with ADHD. Postgrad Med. 2010; 122(1): 184–191.Google Scholar
115. Focalin® Dexmethylphenidate Hydrochloride Tablets, CII Full Prescribing Information. Novartis Pharmaceuticals Corporation, East Hanover, NJ; 2013.Google Scholar
116. Desoxyn® Methamphetamine Hydrochloride Tablets, USP, CII Full Prescribing Information. Recordati Rare Diseases Inc., Lebanon, NJ; 2015.Google Scholar
117. Birmaher, B, Greenhill, LL, Cooper, TB, Fried, J, Maminski, B. Sustained-release methylphenidate: pharmacokinetic studies in ADDH males. J Am Acad Child Adolesc Psychiatry. 1989; 28(5): 768–772.Google Scholar
118. Evekeo™ (Amphetamine Sulfate Tablets, USP), CII Full Prescribing Information. Arbor Pharmaceuticals LLC, Atlanta, GA; 2015.Google Scholar
119. Concerta® (Methylphenidate HCl) Extended-Release Tablets, CII full Prescribing Information. Janssen Pharmaceuticals Inc., Titusville, NJ; 2015.Google Scholar
120. Zenzedi® Dextroamphetamine Sulfate Tablets, CII Full Prescribing Information. Arbor Pharmaceuticals LLC, Atlanta, GA; 2014.Google Scholar
121. Dexedrine® (Dextroamphetamine Sulfate) Spansule® Sustained-Release Capsules and Tablets, CII Full Prescribing Information. Amedra Pharmaceuticals LLC, Horsham, PA; 2015.Google Scholar
122. Procentra® Dextroamphetamine Sulfate Oral Solution, CII Full Prescribing Information. Independence Pharmaceuticals LLC, Newport, KY; 2015.Google Scholar